Skip to main content
Signal8

Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results

$VXRTPress releaseNov 5, 2026, 4:05 PM ET

Vaxart reported Q3 2026 revenue of $10.6 million, down from $72.4 million in Q3 2025, with the net loss widening to $17.7 million ($0.07 per share) from $8.1 million ($0.04). Cash and short-term investments stand at $65.5 million with a runway only into Q2 2027, and the company says it is exploring partnerships and non-dilutive funding to extend it. Topline data from the ~5,400-participant Phase 2b COVID-19 trial is now expected by mid-year 2027, and Vaxart has received $278.0 million cumulatively under its BARDA contract. The company also received a European patent protecting its norovirus vaccine through at least 2036 and appointed retired Vice Admiral Dr.

Key figures

Revenue
10600000
Revenue Yoy
-85%
Net loss
17689000
Ga expense
5074000
Rd expense
22829000
Cash runway
into Q2 2027
Prior year revenue
$72.4 million
Prior year net loss
$8.1 million
Cash and investments
$65.5 million
Phase 2b data timing
mid-year 2027
Barda cumulative payments
$278.0 million
Covid phase2b participants
400 sentinel + ~5,000 main cohort

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.